Not for human consumption, veterinary use, or clinical administration. Sold exclusively to qualified laboratories and researchers for in-vitro study.
Ipamorelin is a pentapeptide GH secretagogue that acts on the ghrelin receptor (GHS-R1a) to stimulate growth-hormone release from the anterior pituitary. It was developed as a selective alternative to earlier GHRPs such as GHRP-2 and GHRP-6, and has been widely studied for its relatively clean receptor-selectivity profile — stimulating GH release with comparatively little impact on cortisol and prolactin levels in preclinical models.
Research on Ipamorelin has examined its dose-response relationship in GH-secretion models, its interaction with endogenous GHRH signalling, and how ghrelin-receptor agonism influences pituitary somatotroph activity. Its selectivity has made it a useful pharmacological tool for researchers who need to isolate GH-pathway effects without confounding activity on the HPA axis.
Studies have also explored Ipamorelin in the context of GH pulse timing and amplitude, particularly in models characterising the kinetics of pulsatile GH secretion and how different GHRPs compare. It is commonly used as a reference GHRP in comparative secretagogue research.
myPEPT supplies Ipamorelin at ≥99% verified purity with a Certificate of Analysis from independent laboratory testing. It ships lyophilised across the EU in research-grade packaging.
What researchers should know: Ipamorelin is a research peptide supplied for laboratory use only. It is not approved for human use as a therapeutic compound and is not for human consumption or injection. Always follow your institution's compound-handling guidelines and applicable local regulations when working with GH-related research peptides.
For research use only. This product is intended exclusively for in-vitro research and laboratory applications. Not approved for human or animal consumption, medical treatment, or therapeutic use.

